The nsp2 Replicase Proteins of Murine Hepatitis Virus and Severe Acute Respiratory Syndrome Coronavirus Are Dispensable for Viral Replication by Graham, Rachel L. et al.
JOURNAL OF VIROLOGY, Nov. 2005, p. 13399–13411 Vol. 79, No. 21
0022-538X/05/$08.000 doi:10.1128/JVI.79.21.13399–13411.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
The nsp2 Replicase Proteins of Murine Hepatitis Virus and Severe
Acute Respiratory Syndrome Coronavirus Are Dispensable
for Viral Replication
Rachel L. Graham,2,3 Amy C. Sims,4 Sarah M. Brockway,2,3 Ralph S. Baric,4
and Mark R. Denison1,2,3*
Departments of Pediatrics1 and Microbiology and Immunology2 and Elizabeth B. Lamb Center for Pediatric
Research,3 Vanderbilt University Medical Center, Nashville, Tennessee, and Department of Epidemiology,
School of Public Health, University of North Carolina, Chapel Hill, North Carolina4
Received 21 June 2005/Accepted 9 August 2005
The positive-stranded RNA genome of the coronaviruses is translated from ORF1 to yield polyproteins that
are proteolytically processed into intermediate and mature nonstructural proteins (nsps). Murine hepatitis
virus (MHV) and severe acute respiratory syndrome coronavirus (SARS-CoV) polyproteins incorporate
16 protein domains (nsps), with nsp1 and nsp2 being the most variable among the coronaviruses and having
no experimentally confirmed or predicted functions in replication. To determine if nsp2 is essential for viral
replication, MHV and SARS-CoV genome RNA was generated with deletions of the nsp2 coding sequence
(MHVnsp2 and SARSnsp2, respectively). Infectious MHVnsp2 and SARSnsp2 viruses recovered from
electroporated cells had 0.5 to 1 log10 reductions in peak titers in single-cycle growth assays, as well as a
reduction in viral RNA synthesis that was not specific for any positive-stranded RNA species. The nsp2
mutant viruses lacked expression of both nsp2 and an nsp2-nsp3 precursor, but cleaved the engineered
chimeric nsp1-nsp3 cleavage site as efficiently as the native nsp1-nsp2 cleavage site. Replication complexes in
MHVnsp2-infected cells lacked nsp2 but were morphologically indistinguishable from those of wild-type
MHV by immunofluorescence. nsp2 expressed in cells by stable retroviral transduction was specifically
recruited to viral replication complexes upon infection with MHVnsp2. These results demonstrate that while
nsp2 of MHV and SARS-CoV is dispensable for viral replication in cell culture, deletion of the nsp2 coding
sequence attenuates viral growth and RNA synthesis. These findings also provide a system for the study of
determinants of nsp targeting and function.
Positive-stranded RNA viruses express polyproteins from
their input genome RNA that are proteolytically processed by
viral and cellular proteinases to yield nonstructural proteins,
structural proteins, or both. This strategy results in evolution-
ary, organizational, and functional linkages between protein
domains at the levels of RNA sequence, protein translation,
proteolytic processing at specific cleavage sites, and functions
of intermediate precursor proteins and mature proteins. The
multiple points of regulation present a formidable theoretical
barrier to extensive deletions or insertions in polyproteins.
Several groups working with positive-stranded RNA viruses
have reported deletions of portions of protein domains or the
generation of viruses whose extensive defects in replication
require rescue by replicons or helper viruses (16, 26, 29, 32, 34,
38, 39, 44, 48). However, for animal positive-stranded RNA
viruses, we have identified no published reports of autono-
mously replicating mutant viruses with deletions of complete
mature protein domains within polyproteins. Thus, the avail-
able experimental evidence has suggested that structural and
functional features of positive-stranded RNA virus polyprotein
domains are essential for virus replication.
Coronaviruses contain 27- to 32-kb positive-stranded RNA
genomes (Fig. 1). The 5-most open reading frame (ORF),
ORF1, also referred to as the replicase gene, is translated in
the host cell cytoplasm into ORF1a and ORF1ab polyproteins
containing up to 16 protein domains that are co- and post-
translationally processed by virus-encoded proteinases into in-
termediate precursors and mature nonstructural proteins
(nsps). All analyzed nsps of murine hepatitis virus (MHV) and
severe acute respiratory syndrome coronavirus (SARS-CoV)
localize to virus-induced cytoplasmic double-membrane vesi-
cles that are the sites of viral RNA synthesis and are referred
to as replication complexes (18, 36).
Based on the numbering of nsps reported for SARS-CoV,
the orthologs of coronavirus nsps serve confirmed (nsps 3, 5,
12, and 13), predicted (nsps 12, 14, 15, and 16), or unknown
(nsps 1, 2, 4, 6, and 7 to 10) functions in replication as well as
possible roles in virus-host interactions (nsps 1, 3, 4, and 6) and
virulence (nsp14). In ORF1a, nsp3 encodes either one or two
papain-like proteinases (PLPs), and nsp5 is a 3C-like proteinase
(1, 30). ORF1b encodes of the putative viral RNA-dependent
RNA polymerase (nsp12), helicase (nsp13), and RNA-process-
ing enzymes: a putative 3-5 exonuclease (nsp14), a poly(U)-
specific endonuclease (nsp15), and a putative ribose 2-O-
methyltransferase (nsp16) (17, 23, 24, 28, 42). In addition, an
MHV nsp14 mutant retains wild-type growth in culture but is
attenuated for replication and virulence in mice, suggesting
that nsp14 has specific roles in pathogenesis (43).
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Coronaviruses are divided into three groups (groups 1, 2,
and 3) based on comparisons of serotype specificity and ge-
nome organization, with MHV as a prototype group 2 corona-
virus. Amino acid sequence identity of replicase polyproteins
from different groups varies from less than 30% to over 60%
(37), with the most variability occurring in the protein domains
upstream of the nsp3 orthologs. Variability in this region in-
cludes differences in the sizes of nsps 1 and 2 as well as in
amino acid sequence identity, with the most variation observed
between coronavirus groups rather than among different coro-
naviruses within a given group. Because nsps 1, 2, and 3 are
processed by one or two papain-like proteinases in nsp3, it has
been suggested that the proteins encoded in this region have
coevolved with nsp3 and may mediate group- and/or host-
specific functions within the viral life cycle (12, 53, 54).
SARS-CoV is most closely related to group 2 coronaviruses
such as MHV in identity and similarity from nsp4 through
nsp16 (Fig. 1) (19, 37, 42). In addition, SARS-CoV retains the
general organization and sizes of nsps 1, 2, and 3 most similar
to group 2 coronaviruses (42, 46). However, there also are
important differences between nsps 1, 2, and 3 of MHV and
SARS-CoV. First, there is very limited identity or similarity
between nsp1 and nsp2 of MHV and SARS-CoV (37). In
addition, MHV has two papain-like proteinase activities in
nsp3, the first of which (PLP1) mediates cleavage at cleavage
site 1 (CS1) between nsp1 and nsp2 and at cleavage site 2
(CS2) between nsp2 and nsp3, and the second of which (PLP2)
mediates cleavage at cleavage site 3 (CS3) between nsp3 and
nsp4 (3, 15, 22, 25). In contrast, SARS-CoV has only the
functional ortholog of PLP2 in nsp3 to mediate all three cleav-
age events (Fig. 1) (46).
Processing of the nsp 1 to 3 region of group 2 and group
2-like coronaviruses is likely an ordered process consisting of
co- and posttranslational processing events. nsp1, a 28-kDa
protein previously referred to as p28, is the first protein to be
processed from the nascent polyprotein following translation
of the proteinase domains within nsp3 (12). nsp2 and nsp3
likely exist as precursor proteins prior to their processing into
mature nsp2 and nsp3 products. Due to the large size of this
nsp2-3 precursor, previous studies have identified it as a
290-kDa (12) or a 250-kDa (40) product based on migration on
sodium dodecyl sulfate (SDS)-polyacrylamide gel electro-
phoresis (PAGE). Subsequent processing then yields mature
nsp2, a 65-kDa product (12, 40), and nsp3, a high-molecular-
weight product with a predicted molecular mass of 222 kDa
and estimated observed molecular masses of 240 kDa (12) and
210 kDa (40). Similarly sized species have been observed for
SARS-CoV, and pulse-chase studies suggest the processing
events follow a similar, if not identical, sequential order (19).
Reverse genetic systems for both MHV and SARS-CoV (47,
51, 52) provide a powerful tool to study requirements for
protein expression, processing, and function during replication
of these two viruses as well as allow direct comparisons of
conserved protein domains, processing events, or amino acid
residues. The nsp2 protein is an attractive target for genetic
studies, since it has been reported that engineered mutations
that eliminate cleavage at CS1 between nsp1 and nsp2 yield
infectious virus (13), suggesting that nsp2 either retains func-
tion in an uncleaved form or has a function that is dispensable
for viral replication. Still, it is not known if nsp2, either as a
mature protein or as a component of the coronavirus polypro-
tein, is absolutely required for viral replication.
In the present study, we sought to determine whether the
nsp2 proteins of the coronaviruses MHV-A59 (hereafter
MHV) and SARS-CoV were required for viral replication or
for processing at the flanking cleavage sites. Reverse genetic
deletion of the nsp2 domains of the MHV and SARS-CoV
polyproteins allowed recovery of infectious mutants with de-
fects in growth and RNA synthesis and demonstrated intact
polyprotein processing, including cleavage at engineered chi-
meric nsp1/3 cleavage sites. Taken together, these results dem-
onstrate that the nsp2 domains of the MHV and SARS-CoV
replicase polyproteins are not required for viral replication.
These results suggest that there is significant structural and
functional flexibility within the coronavirus polyprotein and
that ORF1 encodes at least one and perhaps several protein
domains that may be dedicated to functions distinct from pro-
duction of infectious virus.
MATERIALS AND METHODS
Wild-type virus and cells. Murine hepatitis virus strain A-59 (MHV) or re-
combinant wild-type murine hepatitis virus (MHV-wtic) (13, 43) was used as the
wild-type control in all MHV experiments. MHV-A59 reference sequences
AY910861 and AY700211 were used for cloning studies. Delayed brain tumor
(DBT) cells (21) and baby hamster kidney cells expressing the MHV receptor
(BHK-MHVR) (9, 10) were grown in Dulbecco’s modified Eagle’s medium
(DMEM) that contained 10% fetal bovine serum (FBS) for all experiments.
Medium for BHK-MHVR cells was supplemented with G418 (0.8 mg/ml) for
selection of cells expressing the receptor.
FIG. 1. MHV and SARS-CoV ORF1 organization. The MHV ge-
nome is 31.3 kb in length, and the SARS-CoV genome is 29.7 kb in
length. ORF1 comprises 21.7 kb of the MHV genome and 21.5 kb of
the SARS-CoV genome. MHV contains six downstream ORFs (ORFs
2 to 7), and SARS-CoV contains eight downstream ORFs (ORFs 2
to 9). Schematics are not to scale. ORF1 is translated into a 500-kDa
ORF1a polyprotein (major product) or an 800-kDa ORF1ab poly-
protein (minor product). The mature protein domains of ORF1ab are
indicated with nonstructural protein (nsp) numbers. Papain-like pro-
teinase domains (PLP1 and PLP2 for MHV, PLP for SARS-CoV;
white boxes within nsp3) process nsps 1, 2, and 3 (indicated in dark
gray), and 3C-like proteinases (3C, light gray box, nsp5) process nsps
4 to 16. The molecular masses of nsps 1, 2, 3, and 8 are indicated, in
kDa, below the proteins, and papain-like proteinase cleavage sites 1
to 3 (CS1, CS2, and CS3) are indicated. Black bars beneath the sche-
matic indicate proteins generated to induce the rabbit polyclonal an-
tibodies used in this study. Antibody numbers (VU prefix) are given for
MHV above the bars and for SARS-CoV below the bars.
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Severe acute respiratory syndrome coronavirus Urbani strain (SARS-Urbani, or
SARS-CoV in this report) and/or assembled wild-type SARS-CoV (SARS-wtic)
were used as wild-type controls in all SARS-CoV experiments. SARS-CoV
Urbani reference sequence AY278741 was used for cloning studies. African
green monkey kidney (Vero-E6) cells were grown in DMEM that contained 10%
FBS, kanamycin (0.25 g/ml), and gentamicin (0.05 g/ml) for all experiments.
Generation of nsp2-expressing cells. To generate DBT cells stably transduced
to express nsp2, the pBabe-puro vector system derived from murine Moloney
leukemia virus (33) was used (kindly provided by Chris Aiken, Vanderbilt Uni-
versity). To clone the nsp2 coding sequence (MHV-A59 nucleotides 951 to 2705)
into the pBabe-puro vector, PCR was performed using the MHV infectious
cDNA fragment A plasmid (pCR-XL-TopoA) (52) as the template. Primers
were designed to incorporate translation initiation and translation termination
codons flanking the nsp2 sequence as well as restriction sites (5 SnaBI and 3
SalI) to facilitate subcloning nsp2 into pBabe-puro.
The sequences of the primers are (sense) 5-TAC GTA ATG GTT AAG CCC
ATC CTG TTT G-3 and (antisense) 5-GTC GAC TCA CGC ACA GGG AAA
CCT CC-3. The PCR product was gel purified and cloned into pGEM-T-easy
(Promega), and the T7 and SP6 primers were used to sequence across the nsp2
coding region to verify the intended sequence. Primer-generated restriction sites
(5 SnaBI and 3 SalI) were then used to subclone the nsp2 sequence into the
pBabe-puro vector to generate pBabe-nsp2.
To produce replication-defective retroviruses, human 293T cells (approxi-
mately 2  106 cells) in a 100-mm culture dish were cotransfected with pHCMV-
VSVg (encoding the vesicular stomatitis virus envelope glycoprotein), pCL-
ampho (encoding Moloney murine leukemia virus gag and pol), and either
pBabe-nsp2 or the pBabe-puro vector using calcium phosphate as previously
described (8, 50). The transfected cells were incubated at 35°C for 16 h in
DMEM supplemented with 10% FBS to allow calcium phosphate precipitation.
The transfection medium was then aspirated and the cells were incubated at 35°C
for 48 h in 4 ml of fresh DMEM supplemented with 10% FBS. To harvest
retroviral particles, the medium was clarified by centrifugation at 1,000  g,
passed through 0.45-m-pore-size syringe filters, and frozen in aliquots at
80°C. The replication-defective retroviral particles are referred to as VpBabe-
nsp2 and VpBabe-vec.
To create nsp2-expressing and vector control cells, DBT cells were grown to
20% confluence in 60-mm cell culture dishes and then transduced with either
VpBabe-nsp2 or VpBabe-vec. Equal amounts (1:1) of the filtered retrovirus-
containing supernatants and DMEM supplemented with 10% FBS and Poly-
brene (8 g/ml) were added to cells in a final volume of 2 ml. The cells were
cultured at 37°C for 16 h and then the transduction medium was replaced with
fresh warm DMEM supplemented with 10% FBS. At 48 h posttransduction, the
cells were transferred to 75-cm flasks and incubated in DMEM supplemented
with 10% FBS and puromycin (1 g/ml) to select cells that had stably integrated
the retroviral vectors. Pools of stably transduced cells were maintained in puro-
mycin selection medium for at least 2 weeks prior to assaying expression using
immunofluorescence and immunoprecipitation assays (not shown). DBT cells
stably expressing nsp2 are referred to as DBT-nsp2, and the control cells that
were stably transduced with vector only are referred to as DBT-vec.
Antibodies. Most of the rabbit polyclonal antibodies used in biochemical
experiments have been previously described. For MHV, these include anti-nsp1
(VU221) (7), anti-nsp2 (VU154) (41), and anti-nsp8 (VU123) (5). For SARS-
CoV, these include anti-nsp1 (VU231), anti-nsp2 (VU239), anti-nsp3 (VU 233),
and anti-nsp8 (VU249) (37). These antibodies are further detailed in Table 1.
The mouse monoclonal antibody directed against the structural protein nucleo-
capsid (anti-N, J3.3) was generously provided by John Fleming (University of
Wisconsin, Madison).
Rabbit polyclonal antibodies against MHV nsp3 (VU164) were generated by
Cocalico, Inc. (Reamstown, PA) using a recombinant nsp3 protein fragment as
the antigen. All nsp3 nucleotide and amino acid numbers correspond to the
MHV sequence reported before (2). Nucleotides 2709 to 3746 (ORF1 amino
acids G833 to E1179) corresponding to the N terminus of nsp3 were amplified by
reverse transcription PCR using purified MHV genomic RNA as the template.
Primer-generated restriction sites (5 NcoI and 3 XhoI) were used to subclone
the PCR fragment into the pET23d bacterial expression vector (Novagen). A
38-kDa histidine-tagged protein was expressed in Escherichia coli BL21 cells,
isolated using nickel resin chromatography according to the manufacturer’s pro-
tocol, and further purified by SDS-PAGE and electroelution (Bio-Rad) as pre-
viously described (5).
Construction of mutant MHV and SARS-CoV infectious cDNA fragment A
plasmids. Deletions of the nsp2 coding sequence were achieved for both viral
infectious cDNAs using PCR and the primers shown in Table 2. For all primer
sets, primers A and B generated an A/B PCR product, and primers C and D
generated a C/D PCR product. For all MHV reactions, the MHV infectious
cDNA fragment A construct (pCR-XL-TopoA), which consists of nucleotides 1
to 4882, was used as template DNA (52), and the coding region of nsp2 corre-
sponds to nucleotides 951 to 2705 and amino acids Val248 to Ala832. For all
SARS-CoV reactions, the SARS-CoV infectious cDNA fragment A construct
(pSARS-icA), which consists of nucleotides 1 to 4419, was used as a template
(51) and the coding region of nsp2 corresponds to nucleotides 805 to 2718 and
amino acids Ala181 to Gly818. Mutant fragment A constructs for VURG 22 and
VURG 23 were constructed using the class IIs restriction enzyme method (52) in
which products A/B and C/D were ligated and cloned into the vector at unique
5 SacII and 3 NdeI sites. The mutant fragment A construct for SARSnsp2 was
constructed by the class IIs restriction enzyme method and was cloned into the
vector at unique 5 BglII and 3 NdeI sites. Successful deletions of the nsp2
coding sequences were confirmed by restriction digestion and sequencing.
Generation of MHV and SARS-CoV nsp2 mutant viruses. Viruses containing
the PCR-generated deletion of the nsp2 coding sequence were produced using
the infectious cDNA assembly strategies for MHV-A59 and SARS-CoV as pre-
viously described, with modifications (13, 43, 51, 52). Briefly, for MHV, plasmids
containing the seven cDNA cassettes of the MHV genome were digested using
MluI, BsmBI, and SfiI for fragment A, BglI and BsmBI for fragments B and C,
BsmBI and NciI for fragments D and E, BsmBI for fragment F, and SfiI and
BsmBI for fragment G. Digested, gel-purified fragments were ligated in a total
reaction volume of 170 l overnight at 16°C. Following chloroform extraction
and isopropanol precipitation of ligated DNA, capped, polyadenylated full-
length RNA transcripts of MHV infectious cDNA were generated in vitro using
the mMessage mMachine T7 transcription kit (Ambion) following the manufac-
turer’s protocol with modifications. Fifty-microliter reactions were supplemented
with 7.5 l of 30 mM GTP, and transcription was performed at 40.5°C for 25 min,
37.5°C for 50 min, and 40.5°C for 25 min.
In parallel, capped, polyadenylated RNA transcripts encoding the MHV nu-
cleocapsid protein (N) were generated in vitro using N cDNA generated from
PCR (52). N transcripts and mutant MHV transcripts were then mixed and
electroporated into BHK-MHVR cells. Briefly, BHK-MHVR cells were grown
TABLE 1. MHV and SARS-CoV replicase antibodies
Virus Protein Antiserum Protein detected andsize (kDa) Use
a Amino
acids Reference
MHV nsp1 VU221 nsp1 (28) IP 1–247 7
nsp2 VU154 nsp2 (65) IP, IF 248–521 41
nsp2-3 (275)
nsp3 VU164 nsp3 (210) IP 833–1179 This report
nsp2-3 (275)
nsp8 VU123 nsp8 (22) IP 4015–4208 5
SARS-CoV nsp1 VU231 nsp1 (20) IB 1–227 37
nsp2 VU239 nsp2 (70) IB 228–818 37
nsp3 VU233 nsp3 (213) IB 819–1154 37
nsp8 VU249 nsp8 (22) IB 3920–4117 37
a IP, immunoprecipitation; IF, immunofluorescence; IB, immunoblot. Use refers to the application of the antibody in this report.
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to subconfluence, trypsinized, then washed twice with phosphate-buffered saline
(PBS) and resuspended in PBS at a concentration of 107 cells/ml. Six hundred
microliters of cells was then added to RNA transcripts in a 4-mm gap electro-
poration cuvette (BTX), and three electrical pulses of 850 V at 25 F were
delivered with a Bio-Rad Gene Pulser Xcell electroporator. Transfected cells
were then seeded onto a layer of 106 uninfected DBT cells in a 75-cm2 flask and
incubated at 37°C for 30 h.
For SARS-CoV, plasmids containing the six cDNA cassettes of the SARS-
CoV genome were restriction-digested with MluI and BglI for fragment A, BglI
for fragments B, C, D, and E, and BglI and NotI for fragment F. Digested
fragments were then gel purified, ligated, and transcribed as above. SARS-CoV
RNA and SARS-CoV N transcripts were then electroporated into 800 l of
107 cells/ml Vero-E6 cells (450 V at 50 F) and then seeded in a 75-cm2 flask and
incubated at 37°C for 72 h. Virus viability was determined by cytopathic effect
(syncytium formation for MHV, cell rounding for SARS-CoV), and progeny
were passaged and clones were isolated by plaque assay. RNA was recovered
from infected cell monolayers from both MHV and SARS-CoV infections using
TRIzol (Invitrogen) according to the manufacturer’s instructions, and reten-
tion of introduced mutations was verified by reverse transcription-PCR and
sequencing.
Viral growth assays. For viral growth determination, DBT cells were infected
at a multiplicity of infection (MOI) of 5 PFU/cell with MHV, and Vero-E6 cells
were infected at an MOI of 1 PFU/cell with SARS-CoV. Following a 45-minute
adsorption with rocking at room temperature, medium was aspirated, and cells
were washed three times with PBS and supplemented with warm medium. Cells
were then incubated at 37°C. Aliquots of medium were collected from 1 to 24 h
postinfection (p.i.), and virus titers were determined by plaque assay as described
previously (27).
Protein immunoprecipitations and immunoblots. For protein labeling and
immunoprecipitation experiments, cells were infected with MHV and incubated
at 37°C. At 4.5 h p.i., medium was aspirated and replaced with medium lacking
methionine and cysteine and supplemented with Actinomycin D (Sigma) at a
final concentration of 20 g/ml. At 6 h p.i., cells were labeled with [35S]methi-
onine/cysteine ([35S]Met/Cys) at a concentration of 0.08 mCi/ml. Radiolabeled
cells were lysed in 1 ml no-SDS lysis buffer (1% NP-40, 0.5% sodium deoxy-
cholate, 150 mM sodium chloride, and 50 mM Tris, pH 8.0) at the indicated
times p.i. Cellular debris and nuclei were pelleted by centrifugation at 1,500  g
for 5 min at 4°C, and the supernatant was transferred to a fresh tube. One
hundred microliters of cell lysate was subsequently used per 1 ml of immuno-
precipitation reaction buffer. Lysates that were boiled prior to immunoprecipi-
tation were boiled for 5 min in SDS at a final concentration of 1%. The lysate was
combined with protein A-Sepharose beads and a 1:200 dilution of antibody in
no-SDS lysis buffer supplemented with 1% SDS. After incubation at 4°C for 4 h,
beads were pelleted and washed with low-salt lysis buffer (no-SDS lysis buffer
with 150 mM NaCl) followed by high-salt lysis buffer (no-SDS lysis buffer with
1 M NaCl) and a final low-salt wash. After rinsing, 30 ml of 2X SDS loading
buffer (8% SDS, 0.2 M Tris, pH 8.8, 4 mM EDTA, 0.1% bromophenol blue, 40%
glycerol, 0.5 M dithiothreitol) was added to the pelleted beads and boiled for
5 min prior to electrophoresis of the supernatant on 5 to 18% SDS-PAGE gels.
SARS-CoV-infected cells were lysed in buffer containing 20 mM Tris-HCl, pH
7.6, 150 mM NaCl, 0.5% sodium deoxycholate, 1% Nonidet P-40, and 0.1% SDS,
and tested to confirm inactivation (11). Following centrifugation at 16,000  g
for 2 min to pellet nuclei, supernatants were treated with 1 volume of 10 mM
EDTA/0.9% SDS. Lysates were then heated twice at 90°C for 30 min prior to use.
Immunoblots to detect SARS-CoV proteins were then performed as described
(37). Images were processed using Adobe Photoshop CS.
Metabolic labeling of viral RNA. For metabolic labeling of MHV viral RNA,
DBT cell monolayers (1.5  106 cells) were either mock infected or infected at
an MOI of 5 PFU/cell. Virus was adsorbed for 30 min at room temperature.
Medium was then aspirated and replaced with fresh, warm medium. Thirty
minutes prior to labeling, actinomycin D was added to the cells at a final
concentration of 20 g/ml. Cells were labeled with 30 Ci [3H]uridine in the
presence of actinomycin D for the time intervals indicated. Cells were washed
once with PBS and then lysed with 700 l of no-SDS lysis buffer. Lysates were
centrifuged at 1,500  g to remove nuclei, and then RNA in 200 l of cytosolic
extract was precipitated using trichloroacetic acid. Precipitated RNA was dried
onto glass microfiber filters (Whatman) using vacuum filtration, and radioactivity
was measured in a liquid scintillation counter (Beckman). Quantitative analysis
was performed using ImageJ (http://rsb.info.nih.gov/ij/).
Genomic and subgenomic RNA analysis by Northern blot. DBT cells (MHV)
or Vero-E6 cells (SARS-CoV) were infected with wild-type or mutant viruses at
an MOI of 5 PFU/cell (MHV) or 1 PFU/cell (SARS-CoV). RNA was harvested
from cells at 10 h p.i. (MHV) or 12 h p.i. (SARS-CoV) in TRIzol (Invitrogen),
isolated according to the manufacturer’s instructions, and resuspended in form-
amide. RNA from approximately 1.7  105 cells was electrophoresed in a 0.6%
agarose/2 M formaldehyde morpholinepropanesulfonic acid (MOPS) gel at
144 V for 4 h. RNA was then transferred to positively charged nylon membrane
(Nytran, Schleicher and Schuell) by downward capillary transfer according to the
manufacturer’s instructions (TurboBlotter, Schleicher and Schuell). Blots were
hybridized overnight at 42°C with 1.5 nM of the appropriate biotinylated deoxy-
oligonucleotide probe in ULTRAhyb-Oligo (Ambion).
Probes were designed to hybridize to a portion of the positive-sense 3 un-
translated region (UTR) of the respective viruses, and their sequences were
5-CTGCAAGTCATCCATTCTGATAGAGAGTG-3 for MHV (13, 49) and
5-GGCTCTTTCAAGTCCTCCCTAATGTTAC-3 for SARS-CoV. Probes
were biotinylated with EZ-Link photoactivatable biotin (Pierce) according to the
manufacturer’s protocol. Following hybridization, probe signal was detected
using the North2South detection kit (Pierce) according to the manufacturer’s
instructions. Images were processed using Adobe Photoshop CS. Quantitative
analysis was performed using ImageJ (http://rsb.info.nih.gov/ij/).
Immunofluorescence detection of viral and stably expressed proteins. DBT
cells or DBT-nsp2 cells grown to 60% confluence on 12-mm glass coverslips were
infected with wild-type or mutant MHV at an MOI of 5 PFU/cell. At 6.5 h p.i.,
medium was aspirated from cells, and cells were fixed and permeabilized in
20°C methanol overnight. Cells were then rehydrated in PBS for 20 min, then
blocked in PBS containing 5% bovine serum albumin. The following steps were
performed in immunofluorescence assay wash solution (PBS containing 1%
bovine serum albumin and 0.05% Nonidet P-40) at room temperature. Blocking
solution was aspirated, and cells were incubated in primary antibody (anti-nsp2,
1:200, and anti-nucleocapsid [anti-N], 1:1,000) for 1 h. Cells were then washed in
immunofluorescence assay wash solution three times for 10 min per wash. Cells
were then incubated in secondary antibody (goat anti-rabbit-Alexa 488, 1:1,000,
and goat anti-mouse-Alexa 546, 1:1,000, Molecular Probes) for 45 min. Cells
were washed again three times for 10 min per wash, followed by a final wash in
PBS, and then rinsed in distilled water. Coverslips were mounted with Aqua-
polymount (Polysciences) and visualized by confocal immunofluorescence mi-
croscopy on a Zeiss LSM 510 laser scanning confocal microscope at 488 and
TABLE 2. Primers used for generation of nsp2 deletion constructs
Primer Sequencea(53 3) Sense Purpose
VURG22/23 A 78AACGGCACTTCCTGCGTGTCCATG  PCR partner for MHV B primers
VURG22 B22 CGTCTCCTCTT953AACACCGCGATAGCCCTTAAG  Mutagenesis for MHV VURG22
VURG22 C22 CGTCTCC2709AAGAAAGTCGAGTTTAACGACAAGCC  Mutagenesis for MHV VURG22
VURG23 B23 CGTCTCCTGCC953AACACCGCGATAGCCCTTAAG  Mutagenesis for MHV VURG23
VURG23 C23 CGTCTCC2706GGCAAGAAAGTCGAGTTTAACGAC  Mutagenesis for MHV VURG23
VURG22/23 D 3885ACTTGCACATATGAGACACAACGTCCCCA  PCR partner for MHV C primers
SARSnsp2 A 30CCAACCAACCTCGATCTCTTGTAGATCTGTT  PCR partner for SARS B primers
SARSnsp2 B GCTCTTCATGC804ACCTCCATTGAGCTCACGAG  Mutagenesis for SARSnsp2
SARSnsp2 C GCTCTTCAGCA2722CCAATTAAAGGTGTAACCTTT  Mutagenesis for SARSnsp2
SARSnsp2 D 3663ACCAAATATGCCTGCTGACAACAATGGTG  PCR partner for SARS C primers
a Underlined nucleotides incorporated for cloning or mutagenesis purposes. Nucleotide sequence position is indicated.
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543 nm with a 40X oil immersion lens. Images were processed and assembled
using Adobe Photoshop CS.
RESULTS
Generation and recovery of MHVnsp2 viruses. To deter-
mine whether the nsp2 domain is required for MHV replica-
tion, cloned genome fragments were engineered to delete the
nsp2 coding sequence (Fig. 2). The nsp2 coding sequence is
bounded by the nsp1-nsp2 cleavage site (cleavage site 1 [CS1]
in this report) and the nsp2-nsp3 cleavage site (cleavage site 2
[CS2]). The P2 to P1 residues of CS1 and CS2 are not iden-
tical in MHV. CS1 is composed of P2-ArgGly2Val-P1, while
CS2 is composed of P2-CysAla2Gly-P1, and thus a direct
juxtaposition of nsp1 and nsp3 would result in a chimeric
nsp1/3 cleavage site, P2-ArgGly2Gly-P1. We therefore main-
tained the amino acid sequence corresponding to P2-P1 of the
CS1 cleavage site, incorporating the first amino acid of nsp2 to
complete the cleavage site at P1 (V248), since in vitro and
reverse genetic studies of cleavage at this site identified these
residues as key determinants of cleavage (13, 15, 22).
Two different constructs were generated with different P2
residues: VURG22 maintains the amino-terminal coding se-
quence of nsp3 (833GKK) and VURG23 deletes the first Gly833
of nsp3, generating a P sequence that more closely resembles
the native CS1. Mutated genome fragment A cDNAs were
used to assemble in vitro full-length MHV genome cDNAs
lacking the nsp2 coding sequence. The full-length cDNA was
used to direct in vitro transcription of full-length genomic
RNA, which was electroporated into BHK cells expressing the
MHV receptor (BHK-MHVR cells) (13, 52). The electropo-
rated cells were seeded onto subconfluent monolayers of DBT
cells and monitored for cytopathic effect for 24 to 48 h.
Cells electroporated with the VURG22 and VURG23 ge-
nomes demonstrated a progressive cytopathic effect (syncytium
formation) that began at 24 h postelectroporation and com-
pletely involved the seeded monolayer by 48 h postelectropo-
ration. When clarified supernatant medium from the electro-
porated cells was used to infect fresh monolayers of DBT cells,
80% of cells were involved in syncytia by 12 h p.i., confirming
the presence of infectious progeny virus. Total RNA was ex-
tracted from the infected monolayers and sequenced by re-
verse transcription-PCR from nucleotide 645 within the nsp1
coding region to nucleotide 3312 within the nsp3 coding re-
gion, confirming that the modified sequence with nsp2 deletion
in recovered virus matched that introduced in the cDNA frag-
ment (data not shown). No other nucleotide changes were
identified in this region. Since the entire 32-kb genome of
recovered viruses was not sequenced, additional mutations
outside of this region cannot be ruled out. Nevertheless, these
results demonstrated that deletion of the nsp2 coding sequence
from MHV allowed recovery of infectious virus and that no
other mutations in the proteins flanking nsp2 were associated
with recovery of virus.
Deletion of MHV nsp2 coding sequence results in wild-type
growth kinetics but decreased virus titer. To determine the
effect of nsp2 deletion on MHV growth, single-cycle growth
assays were performed in which cell monolayers were in-
fected with an MOI of 5 PFU/cell of wild-type recombinant
virus (MHV-wtic) or the MHVnsp2 viruses VURG22 and
VURG23. Samples of cell supernatant were harvested at time
points from 1 to 24 h p.i., and viral titer was determined by
plaque assay (Fig. 3). Infection with MHV-wtic virus resulted
in peak titers of 6.7  107 PFU/ml at 12 h p.i. For VURG22
and VURG23, titers achieved at 12 h p.i. were 0.5 log10
reduced for both mutants (1.2  107 PFU/ml peak for both
viruses). These results demonstrate that deletion of nsp2 al-
lows virus growth in cell culture with similar kinetics as wild-
type virus and with only a modest reduction in peak titer. The
growth curves of VURG22 and VURG23 were indistinguish-
able, demonstrating that the strategies resulting in different
chimeric nsp1/3 cleavage sites yielded virus with similar growth
fitness.
Polyprotein expression and processing in MHVnsp2
mutants. To determine the effects of nsp2 deletion on expres-
sion and processing of nsp1, nsp3, and the remainder of the
replicase polyprotein, cytoplasmic lysates of cells infected with
wild-type MHV and MHVnsp2 mutants were immunopre-
cipitated with antibodies against nsp1 (28 kDa), nsp2 (65 kDa),
nsp3 (210 kDa), and the downstream, 3CLpro-processed nsp8
(22 kDa). To detect nsp3 produced in MHV-infected cells, a
polyclonal antiserum was induced in rabbits against a recom-
binant protein polypeptide expressed in E. coli containing the
amino-terminal 346 amino acids of nsp3 (amino acids G833 to
E1179). The anti-nsp3 antiserum (VU164) was first used to
immunoprecipitate proteins from lysates of mock-infected or
MHV-infected DBT cells (Fig. 4A). The anti-nsp3 antibodies
detected a 210-kDa band in MHV-infected cells, which was not
detected by immune serum in mock-infected cells or by pre-
immune serum from the same rabbit in virus-infected cells and
which was consistent with the predicted mass of MHV nsp3.
FIG. 2. Construction of MHVnsp2 viruses. (Top) The first three
proteins of the replicase polyprotein, nsps 1 to 3, with amino acids at
positions P3 to P3 of the first two cleavage sites (CS1 and CS2) are
shown. Cleavage positions are indicated by downward arrows, and
amino acid residue numbers are indicated. (Middle and bottom) Be-
cause in vitro studies have not determined the minimal sequence
required to allow PLP-mediated processing, deletions of nsp2 were
achieved in two ways. Both deletions maintained the canonical CS1
P2-P1 246RG2V248 to allow rapid processing of nsp1. (Middle)
VURG22 was generated by deletion of amino acids Lys249 to Ala832
of nsp2, resulting in an nsp1/3 juxtaposition with unchanged nsp3
coding sequence directly fused to Val248. (Bottom) VURG23 was
generated by a deletion of the N-terminal amino acid Gly833 of wild-
type nsp3 in addition to amino acids Lys249 to Ala832 of nsp2, so the
nsp1/3 juxtaposition resulted in a cleavage site that more closely re-
sembled that of CS1 P3 to P3.
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The immune anti-nsp3 antibodies also detected a protein of
275 kDa in infected cells. The 275-kDa protein was also
detected when the cell lysate was boiled prior to immunopre-
cipitation with anti-nsp3, demonstrating that it was specifically
recognized by anti-nsp3. The 275-kDa protein was similar to
high-molecular-weight proteins previously detected with other
antibodies (12, 40), and had the mobility of a theoretical nsp2-
nsp3 precursor. These results established the specificity of the
anti-nsp3 antibody and showed it was capable of detecting both
nsp3 and a higher-molecular-weight protein that was a putative
nsp2-nsp3 precursor.
The anti-nsp3 antibodies were then used along with anti-
nsp1, anti-nsp2, and anti-nsp8 to immunoprecipitate lysates
from cells that were mock infected or infected with MHV-wtic
or MHVnsp2 virus in the presence of [35S]Met/Cys from 6 to
10 h p.i. (Fig. 4B). Both nsp2 and the putative nsp2-nsp3
precursor were detected in lysates from cells infected with
MHV-wtic. As predicted from the sequences, neither nsp2
(65 kDa) nor the putative nsp2-nsp3 precursor (275 kDa) was
detected in lysates from cells infected with MHVnsp2 viruses.
In contrast, nsp1 (28 kDa), nsp3 (210 kDa), and nsp8 (22 kDa)
all were detected at comparable levels in MHV-wtic-,
VURG22-, and VURG23-infected cell lysates. Together, these
experiments demonstrated that processing at the nsp3-nsp4
cleavage site was intact, as was the 3CLpro-mediated process-
ing of nsp8. In addition, proteolytic processing at the engi-
neered chimeric nsp1/3 cleavage sites of both MHVnsp2 mu-
tants was complete, based on detection of distinct nsp1 and
nsp3 bands and suggested by the lack of any detectable protein
consistent with an uncleaved 238-kDa nsp1/3 precursor.
Since the P2 residue of the chimeric nsp1/3 cleavage sites no
longer matched the P2 residue of wild-type CS1, these results
demonstrated that the P2 residue in the engineered chimeric
FIG. 3. Growth of MHVnsp2 viruses. DBT cells were infected
with the indicated viruses at an MOI of 5. Samples of supernatant were
taken at the indicated times postinfection, and titers were determined
by plaque assay on DBT cells. wtic, recombinant wild-type control
(MHV-wtic). A representative result from three experiments is shown.
Error bars represent standard deviation across four replicate plaque
assays within the experiment.
FIG. 4. Detection of MHV nsp3 and protein expression of
MHVnsp2 viruses. (A) DBT cells were either mock infected or in-
fected with MHV, and proteins were labeled with [35S]Met/Cys from 6
to 8 h p.i. Following removal of nuclei by centrifugation, equal aliquots
of cell lysate were then immunoprecipitated under the following con-
ditions: using preimmune serum (pre); using anti-nsp3 antibodies (im-
mune), or using anti-nsp3 antibodies following a 5-min boil in the
presence of 1% SDS (boil). Proteins were then resolved by SDS-
PAGE. Viral proteins are indicated to the right of the gel by mass in
kDa. Molecular mass markers are shown to the left, with mass in kDa.
(B) DBT cells were infected with the indicated viruses. Proteins were
labeled with [35S]Met/Cys from 6 to 10 h p.i. Cell lysates were immu-
noprecipitated with anti-nsp1, anti-nsp2, anti-nsp3, and anti-nsp8 an-
tibodies, and proteins were resolved by SDS-PAGE. Proteins are in-
dicated to the right of the gels by nsp number. Molecular mass, in kDa,
is indicated to the left of the gels. nsp2–3 represents the precursor
protein to nsp2 and nsp3 that is detectable in wild-type infections.
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nsp1/3 cleavage site did not abolish or inhibit the processing of
nsp1 from nsp3. The results show that no specific amino acid
sequences or other determinants in nsp2 are required for
cleavage at either the nsp2 amino-terminal CS1 or carboxy-
terminal CS2. Finally, the experiments provide the first direct
genetic evidence from infectious virus that the 275-kDa pro-
tein is the nsp2-nsp3 precursor.
MHVnsp2 mutant viruses have decreased RNA synthesis.
To determine whether the growth defects of the MHVnsp2
mutants were associated with defects in viral RNA synthesis,
cells infected at an MOI of 5 with MHV-wtic or the
MHVnsp2 viruses were metabolically labeled with [3H]uri-
dine in the presence of actinomycin D for 2-h intervals from 3
to 15 h p.i. Total RNA was harvested in TRIzol and measured
for trichloroacetic acid-precipitable incorporation of [3H]uri-
dine (Fig. 5A). The timing of peak incorporation of [3H]uri-
dine into mutant viral RNA was similar to that of MHV-wtic,
occurring between 7 to 9 and 9 to 11 h p.i. However, when
average total incorporation from 7 to 9 and 9 to 11 h was
compared with MHV-wtic, RNA synthesis was reduced for
both VURG22 (48% of MHV-wtic) and VURG23 (44% of
MHV-wtic) (Fig. 5A).
To determine if changes in RNA synthesis were associated
with species of RNA, monolayers of infected, nonradiolabeled
cells were used to harvest RNA for Northern blot analysis of
viral RNA species at 10 h p.i. (Fig. 5B). When total RNA was
probed for positive-strand RNA, all genomic and subgenomic
RNA species were detected. The only distinction between
MHV-wtic and MHVnsp2 mutants was a decrease in the size
of genome RNA, consistent with deletion of 5.6% of the ge-
nome (Fig. 5B). The mobility of other RNA species and the
ratios of viral RNA1 to RNA7 for wild-type and mutant viruses
(0.19 for MHV-wtic, 0.13 for VURG22, and 0.16 for
VURG23) were not significantly different. Thus, the changes in
viral RNA synthesis for the MHVnsp2 mutants reflected an
overall reduction in RNA synthesis, but not a specific regula-
tion or alteration of specific positive strand species.
MHVnsp2 viruses form replication complexes. MHV nsp2
previously has been shown to target to cytoplasmic replication
complexes (6, 41), so we sought to determine if MHVnsp2
mutants demonstrated changes in the formation of replication
complexes in the infected cell cytoplasm in the absence of
nsp2. DBT cells on glass coverslips were infected with MHV-
wtic or the MHVnsp2 viruses for 6.5 h, fixed, and probed by
indirect immunofluorescence with anti-nsp2 and anti-N (nu-
cleocapsid), since N localization is a marker for replication
complexes at early times p.i. (Fig. 6A). DBT cells infected with
wild-type virus demonstrated colocalization of nsp2 and N
protein in discrete cytoplasmic foci, as previously described for
MHV replication complexes. DBT cells that were infected with
MHVnsp2 viruses had a pattern of N localization to punctate
cytoplasmic complexes indistinguishable from that produced
by wild-type virus, while no fluorescent signal was detected in
VURG22- and VURG23-infected cells probed with anti-nsp2.
Thus, the MHVnsp2 viruses are able to form replication
complexes in the absence of nsp2 that are, by indirect immu-
nofluorescence, identical to those of MHV-wtic-infected cells,
indicating that nsp2 is not required for replication complex
formation.
FIG. 5. RNA synthesis of MHVnsp2 viruses. (A) DBT cells in
six-well plates were infected with the indicated viruses at an MOI of 5.
Thirty minutes prior to labeling, medium was aspirated and replaced
with warm medium containing actinomycin D. RNA was labeled with
[3H]uridine for the times indicated, cells were lysed, and [3H]uridine
incorporation was quantitated by scintillation counting of trichloroace-
tic acid-precipitable RNA. Error bars indicate standard deviation of
triplicate trichloroacetic acid precipitations within one experiment. (B)
DBT cells in 60-mm dishes were infected with the indicated viruses.
Cells were lysed at 10 h p.i. in TRIzol, and RNA was isolated. RNA
corresponding to 1.7  105 cells was electrophoresed in a 0.6%
agarose–2 M formaldehyde–MOPS gel and transferred to a nylon
membrane. Positive-stranded RNA species were hybridized with an
antisense, biotinylated oligodeoxynucleotide probe that recognizes the
3 UTR of MHV and visualized following detection by chemilumines-
cence. Relative exposure time is indicated below each blot, and RNA
species are indicated to the right. RNA1 –genomic RNA. RNAs 2 to
7 –subgenomic RNAs.
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Targeting of exogenous nsp2 to replication complexes of
MHVnsp2 viruses. Since MHVnsp2 viruses were capable of
forming replication complexes in the absence of nsp2 expres-
sion, we hypothesized that nsp2 may be targeted to replication
complexes by other viral or virus-induced factors. Thus, we
sought to determine whether exogenously expressed nsp2 was
capable of trans targeting to replication complexes in the ab-
sence of viral nsp2. A system for exogenous expression of nsp2
was developed in which a retroviral construct that expressed
nsp2 was generated (pBabe-nsp2). DBT cells were transduced
and selected for stable expression of pBabe-nsp2 (DBT-nsp2
cells). Growth of DBT-nsp2 cells appeared identical to that of
both nontransduced DBT cells and DBT cells transduced with
the empty pBabe construct (data not shown).
To determine if exogenously expressed nsp2 was capable of
trans-targeting to replication complexes in the absence of viral
nsp2, DBT-nsp2 cells were infected with MHV-wtic or
MHVnsp2 viruses. Cells were then analyzed by indirect im-
munofluorescence to determine the localization patterns of
nsp2 and N. A diffuse distribution of nsp2 was observed in
mock-infected DBT-nsp2 cells, with nsp2 protein detectable in
the cytoplasm and to some extent in the nucleus of the stably
expressing cells (Fig. 6B, top row). No nsp2 protein was de-
tected in DBT cells transduced with the empty pBabe retrovi-
ral construct (DBT-vec cells, data not shown). When the
DBT-nsp2 cells were infected with MHV-wtic, exogenously
expressed nsp2 protein was detected exclusively colocalized
with N in replication complexes (Fig. 6B, second row). In these
cells, no nsp2 was found in the nucleus or diffuse in the cyto-
plasm, suggesting complete retargeting of expressed nsp2 to
the replication complexes.
To determine if the recruitment of exogenous nsp2 to rep-
lication complexes required viral nsp2, DBT-nsp2 cells were
infected with MHVnsp2 viruses. When cells were infected
with MHVnsp2 viruses, the pattern of nsp2 colocalization
with N in putative replication complexes was indistinguishable
from that in MHV-wtic infection. These results demonstrate
that exogenously expressed nsp2 does not target specific mem-
branes in the absence of infection. However, exogenously ex-
pressed nsp2 can be recruited to and retained at replication
complexes in trans. This recruitment does not require viral
nsp2 but rather is mediated by interactions with other viral or
virally induced proteins or RNAs. Finally, these results support
the conclusion that the defect in viral growth and RNA syn-
thesis observed in the nsp2 deletion viruses was not due to an
inability of the viruses to form replication complexes.
Deletion of SARS-CoV nsp2 allows virus recovery, growth,
nsp processing, and viral RNA synthesis. Although SARS-
CoV encodes nsps 1, 2, and 3 that are most similar in organi-
zation and size to the MHV proteins, the observed differences
between MHV and SARS-CoV in this region of their polypro-
teins made it difficult to predict whether deletion of SARS-
CoV nsp2 would allow recovery of viable mutants phenotypi-
cally similar to MHVnsp2 mutants (Fig. 1) (37, 42). To
determine whether the nsp2 domain of the SARS-CoV ORF1
polyprotein was required for viral replication, a construct of
SARS-CoV cDNA fragment A was generated in which the
SARS-CoV nsp2 coding sequence was deleted. Since the P2-
P1 residues of SARS-CoV CS1 and CS2 are identical, the
SARS-CoV nsp1/3 juxtaposition was designed to generate a
true chimeric cleavage site that maintained the native P5-P1 of
nsp1 and the P1-P5 of nsp3 (Fig. 7A).
The SARS-CoV fragment A cDNA lacking the complete
nsp2 coding sequence was used to assemble full-length cDNA
of SARS-CoV, and in vitro-transcribed genomic RNA and N
transcripts were electroporated into Vero-E6 cells. Cells dem-
onstrated a progressive cell rounding cytopathic effect by 72 h
postelectroporation, consistent with a productive cytopathic
infection. RNA derived from plaque-purified virus was sub-
jected to reverse transcription PCR, and sequence analysis of
the region spanning nsp1 through nsp3 (nucleotides 604 to
3019) confirmed the deletion of nsp2 and generation of the
intended chimeric nsp1/3 cleavage site, with no other muta-
tions observed in this region (data not shown). This confirmed
that deletion of the SARS-CoV nsp2 coding sequence allowed
recovery of infectious virus.
The purified SARS nsp2 virus was analyzed for viral
growth, protein processing, and RNA synthesis, as performed
for MHVnsp2 viruses. Infection with SARS-Urbani and
SARS-wtic (recombinant wild-type) virus resulted in titers of
3.6  107 PFU/ml and 5.5  107 PFU/ml, respectively, at 24 h
p.i. (Fig. 7B). For SARSnsp2, titers achieved at 24 h p.i. were
1-log10 reduced (3.5  10
6 PFU/ml) compared to wild-type
infections. These results demonstrate that, as for MHV, dele-
tion of nsp2 of SARS-CoV allows virus growth in cultured cells
with similar kinetics in comparison to wild-type viruses and
with only a modest defect in titer.
To determine whether the decrease in titer observed for
nsp2 deletion virus was associated with alterations in process-
ing at the chimeric nsp1/3 cleavage site or at other cleavage
sites in the polyprotein, mock-infected and infected cell lysates
were analyzed by immunoblot for viral proteins using anti-
SARS nsp1, anti-SARS nsp2, anti-SARS nsp3, and anti-SARS
nsp8 antibodies (Fig. 7C) (37). nsp2 was readily detected dur-
ing SARS-wtic infection but was absent from cells infected
with SARSnsp2. In contrast, nsp1, nsp3, and nsp8 were de-
tected as mature processed proteins in both SARS-CoV- and
SARSnsp2-infected cells. These experiments confirmed the
absence of nsp2 protein in SARSnsp2-infected cell lysates
and the normal processing of nsp3 by papain-like protease and
of nsp8 by 3CLpro. Thus, the growth defect in SARSnsp2 was
not due to inactivation of proteinases or abrogation of polypro-
FIG. 6. Replication complex formation in MHVnsp2-infected cells. (A) DBT cells on glass coverslips were infected with the indicated viruses.
At 6.5 h p.i., cells were fixed and permeabilized in 20°C methanol, rehydrated in PBS, and analyzed by indirect immunofluorescence using
anti-nsp2 (green) and anti-N (red). Yellow pixels represent colocalization as evidenced by overlapping green and red pixels. Cells were imaged on
a Zeiss LSM 510 confocal microscope at 40X magnification. (B) DBT-nsp2 cells (see Materials and Methods) were infected, fixed, stained, and
analyzed by indirect immunofluorescence as in A. Mock cells were mock infected and then treated identically to infected cells. N –nucleocapsid
protein, a marker for replication complexes.
VOL. 79, 2005 CORONAVIRUS nsp2 IS NOT REQUIRED FOR VIRAL REPLICATION 13407
tein processing events. These experiments also extended the
observations with the MHVnsp2 mutant viruses, demonstrat-
ing that a chimeric cleavage site generated by direct juxtapo-
sition of nsp1 and nsp3 coding sequences with no altered or
additional residues can be recognized and cleaved by PLP.
To determine whether the growth defect observed in
SARSnsp2 was due to a defect in the accumulation of any
particular positive-strand species of viral RNA, Northern blot
analysis was performed on RNA extracted from SARS-wtic- or
SARSnsp2-infected Vero-E6 cells using an antisense probe
complementary to the 3 UTR to detect all positive-strand
RNA species (Fig. 7D). The SARSnsp2 virus produced all
genomic and subgenomic RNAs, and the ratios of RNA1 to
RNA9 were comparable to SARS-wtic (0.34 for SARS-wtic
and 0.28 for SARSnsp2). Likewise, a change in electro-
phoretic mobility was observed for genomic RNA (RNA1) of
SARSnsp2, consistent with the calculated 6.4% reduction in
the size of RNA1 of SARSnsp2. These results demonstrate
FIG. 7. Construction and characterization of SARS-CoVnsp2 virus. (A) The first three proteins of the replicase polyprotein, nsps 1 to 3, with
amino acids at positions P3 to P3 of the first two cleavage sites (CS1 and CS2) are shown. Cleavage positions are indicated by downward arrows,
and amino acid residue numbers are indicated. The deletion of SARS-CoV nsp2 was achieved by deleting amino acids Ala181 to Gly818 of the
nsp2 coding sequence, generating an nsp1/3 juxtaposition. (B) Growth of SARS-CoV nsp2 deletion virus. Vero-E6 cells were infected at an MOI
of 1 with the indicated viruses. Samples of supernatant were taken at the indicated times postinfection, and titers were determined by plaque assay
on Vero-E6 cells. SARS Urbani –parent wild-type strain to recombinant SARS-CoV. SARS wtic –recombinant wild-type SARS-CoV control. (C)
Protein expression of SARS-CoV nsp2 deletion virus. Vero-E6 cells were infected with the indicated viruses and harvested at 12 h p.i. Viral
proteins were resolved by SDS-PAGE and detected by immunoblot using SARS-CoV anti-nsp1, anti-nsp2, anti-nsp3, and anti-nsp8 antibodies.
Proteins are indicated to the right of the gels by nsp number. (D) Accumulation of genomic and subgenomic RNAs of SARS-CoV nsp2 deletion
virus. Vero-E6 cells in 60-mm dishes were infected with the indicated viruses. Cells were lysed at 12 h p.i. in TRIzol, and RNA was isolated. RNA
corresponding to 1.7  105 cells was electrophoresed in a 0.6% agarose/2 M formaldehyde/MOPS gel and transferred to a nylon membrane.
Positive-stranded RNA species were hybridized with an antisense, biotinylated oligodeoxynucleotide probe complementary to the 3 UTR and
detected by chemiluminescence. Relative exposure time is indicated to the left of each blot, and RNA species are indicated to the right.
RNA1 –genomic RNA. RNAs 2 to 9 –subgenomic RNAs.
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that deletion of the nsp2 coding sequence of SARS-CoV does
not result in a defect in the production of any particular pos-
itive strand viral RNA species.
DISCUSSION
In this study, we have demonstrated that the nsp2 protein
domain is dispensable for MHV and SARS-CoV replication in
cell culture. We have not identified any published report of the
deletion of a complete mature protein domain from the
polyprotein of a positive-stranded RNA virus that allowed
autonomous replication. Deletions within polyproteins of west-
ern equine encephalitis virus, infectious bovine diarrhea virus,
Moloney sarcoma virus, and others, for instance, have been
reported, but these have not resulted in loss of complete ma-
ture protein domains (31, 35, 48). Whether complete deletions
with autonomous replication have not been attempted or have
been unsuccessful cannot be ascertained from the lack of re-
ports. However, requirements for the maintenance of RNA
structure, RNA replication, protein translation, polyprotein
processing, and protein function have been presumed to im-
pose formidable restrictions on the deletion of mature protein
domains from polyproteins.
The viability and replication competency of the MHV and
SARS-CoV nsp2 deletion mutants argue that, at least for coro-
naviruses, the above theoretical assumptions need to be recon-
sidered. The deletion of the nsp2 domain of the MHV and
SARS-CoV replicase polyproteins was tolerated with only
modest growth and RNA defects and no detectable effect on
polyprotein processing in the recovered mutant viruses. The
experimental results clearly indicate that neither the nsp2 pro-
teins nor the RNA genome sequences encoding nsp2 are re-
quired for generation of infectious virus in cell culture. The
results also demonstrate that the translation and processing of
the ORF1 polyprotein, intermediate precursors, and mature
proteins can occur in the setting of a major engineered dele-
tion of the polyprotein coding sequence.
Whether the coronaviruses are a special case or reflect a pre-
viously uncharacterized “plasticity” within positive-stranded RNA
viruses that express mature proteins from polyproteins, we can
conclude that there may be significantly greater flexibility in
the polyprotein organization, translation, and processing than
had been assumed prior to this study. In addition, the experi-
mental results raise important questions as to possible novel
functions of “replicase gene” proteins during virus infection as
well as conservation of functions between coronaviruses for
proteins that have limited amino acid similarity.
Processing of nsp1, nsp2, and nsp3 precursors and mature
proteins. The delayed cleavage of MHV nsp2 (p65) from a
240-kDa intermediate processed precursor was first reported
in 1995 (12), and subsequent metabolic labeling and protein
processing studies strongly supported a relationship between a
240- to 290-kDa protein and nsp2 and nsp3 (18, 40). The
present study allowed direct comparison of precursors and
mature proteins from viruses containing and lacking nsp2. The
detection of nsp2 (p65) and the 275-kDa protein in MHV-wtic
but complete absence of these proteins in the MHVnsp2
mutants provides direct genetic confirmation that the 275-kDa
protein is an nsp2-nsp3 precursor. Simultaneously, the same
experiments conclusively show that the nsp2-nsp3 precursor is
not required either for nsp3 expression, PLP-mediated prote-
olysis, or virus replication in culture. Recently, an nsp2-nsp3
precursor was reported for SARS-CoV (19). The viability of
the SARS-CoVnsp2 mutant similarly demonstrates that the
SARS-CoV nsp2-nsp3 precursor is not required for growth in
culture.
Our recent study involving MHV nsp2 processing addressed
the determinants of processing at the N-terminal cleavage site
of nsp2, the nsp1-nsp2 cleavage site (CS1) (13). While we
demonstrated in that study that processing determinants at
residues P5 through P5 of CS1 during viral replication con-
formed to those identified in in vitro studies (3, 15), this study
further demonstrates that a chimeric cleavage site, possessing
amino acid residues from the C terminus of nsp1 and the N
terminus of nsp3, was processed, showing that the context of
the cleavage sites can be dramatically altered and still be rec-
ognized and cleaved. Whereas SARS-CoV P2-P1 residues are
identical for the nsp1-nsp2 and nsp2-nsp3 cleavage sites, this is
not the case for MHV. The residues occupying the P2-P1 sites
of the cleavage sites are RG2V for nsp1-nsp2 (CS1) and
CA2G for nsp2-nsp3 (CS2). The chimeras generated in this
study did not assess the effect of directly fusing the C terminus
of MHV nsp1 to the N terminus of nsp3, instead incorporating
the N-terminal amino acid residue of nsp2, Val248, to preserve
the CS1 P2-P1 context.
In spite of this, however, the processing of both SARS-CoV
and MHV nsp1 from nsp3 observed in this study argues that
one of two circumstances may be required to allow PLP-
mediated processing. The first possibility is that only the prox-
imal residues of the cleavage site are required for processing.
In vitro studies identified optimal residues from P6 to P2 for
processing (4, 15, 22) and our results in this study suggest that
the identity of the P1 residue is not critical. However, another
in vitro study suggests that a substrate of at least 69 kDa must
be present for efficient PLP1-mediated processing to occur
(45). Thus, another possibility is that, provided the cleavage
site is accessible to the proteinase, a major factor determining
whether or not cleavage will occur at these sites is the presence
of a suitable upstream amino acid sequence context (context
A) and a suitable downstream amino acid sequence context
(context B). This hypothesis argues that, assuming sufficient
contexts A and B are present, functional cleavage site chimeras
can be generated.
The observed kinetics of nsp 1, 2, and 3 processing in wild-
type infection would suggest that context plays a role in the
availability of cleavage sites and efficiency of processing. This
model would predict that the deletion of nsp2 and juxtaposi-
tion of nsp1 and nsp3 creates a new combination of proximal
cleavage site determinants and contexts A and B that result in
efficient cleavage at the chimeric site. Finally, our previous
study with engineered CS1 cleavage mutants and this study
suggest that amino acid residues in context A may play a more
important role in proteolytic recognition and/or processing
than amino acid residues in context B for PLP-mediated
polyprotein processing (13). This suggests the possibility that
only cleavage site and context determinants in the “upstream”
protein are required for recognition and cleavage by the pro-
teinase in the setting of viral infection. These hypotheses will
be tested by altering the A and B contexts, such as by inserting
a foreign gene with and without proximal cleavage site context
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and testing for cleavage efficiency. Expression of foreign genes
by insertion between the nsp1 and nsp2 coding sequences of a
coronavirus replicon system has been shown for human coro-
navirus 229E, though effects on ORF1 protein expression and
proteolytic processing were not directly assessed (20).
MHV and SARS-CoV nsp2 proteins: distinct sequences with
similar functions? Though SARS-CoV differs in many ways
from other coronaviruses studied to date, it has been stated
that in ORF1, it is most similar to the group 2 coronaviruses
(42). Following the pattern of all other coronaviruses, nsps 1 to
3 of SARS-CoV are the most variable compared with those of
MHV and other coronaviruses, suggesting the possibilities of
positive selective pressure and evolution of virus-specific func-
tions. However, the observations that both MHV and SARS-
CoV tolerate deletion of nsp2 and that these deletion viruses
display remarkably similar phenotypes in growth, RNA synthe-
sis, and protein processing suggest that the nsp2 proteins of
MHV and SARS-CoV may serve similar functions in replica-
tion, or possibly in virus-cell interactions or pathogenesis.
The delayed cleavage of nsp2 from nsp3, the exclusive lo-
calization to replication complexes, and the growth and RNA
defects of the nsp2 deletion mutants all argue that nsp2 may be
serving roles in regulation of global RNA synthesis that, while
not essential, serve to optimize generation of infectious virus.
While a 50% decrease in RNA synthesis and a 1-log10 reduc-
tion in growth may allow propagation in culture, such a “mod-
est” defect might significantly attenuate or abolish replication
or virulence during infection of animals. Testing of the MHV
and SARS-CoV nsp2 deletion mutants in different cell types
and directly in animals for replication and virulence will be
necessary to test these possibilities.
While we propose that the similar phenotypic changes in
MHV and SARS-CoV nsp2 deletion mutants are due to lack of
expression of nsp2 and nsp2-nsp3, we cannot exclude the pos-
sibility that the changes are due to the deletion of 5% of the
viral genomes, with possible effects on RNA synthesis and
growth. The extensive differences in SARS-CoV and MHV
RNA in the nsp2 coding region, along with the lack of pre-
dicted secondary structures, argues against an RNA defect
being responsible for the observed changes. Unambiguous
demonstration that the observed replication and RNA synthe-
sis defects are due to loss of nsp2 or the nsp2-nsp3 precursor
will require complementation of the deficits by exogenously
expressed proteins.
In this study, we demonstrated that nsp2 stably expressed in
DBT cells by retroviral transduction was able to target to the
replication complexes of MHV mutants lacking nsp2 expres-
sion. However, DBT-nsp2 cells generated in this study exhib-
ited a broad range of expression levels of nsp2, but not all cells
were infected during high-MOI infections. Thus, only 5 to 10%
of DBT-nsp2 cells both expressed nsp2 and demonstrated de-
tectable infection. Because of this, we concluded that the mod-
est growth and RNA defects of the MHVnsp2 mutants could
not be directly tested for complementation in this system. Such
studies may require more highly impaired mutants, cells se-
lected for specific levels of protein expression, or alternative
methods of nsp2 expression, such as replicons or heterologous
viruses.
In conclusion, we have engineered and established mutant
MHV and SARS-CoV viruses containing deletions of the nsp2
coding sequence. These viruses did not produce the nsp2 pro-
tein, yet processed other replicase proteins correctly and rep-
licated well in cell culture. These observations demonstrate for
the first time that for the coronaviruses, at least one mature
ORF1 protein domain is dispensable for replication in cell
culture. Furthermore, these results bring to light a previously
uncharacterized flexibility for deletion and reorganization
within the coronavirus replicase polyprotein, providing insights
into the requirements for the formation and function of the
coronavirus replication complex. Finally, these findings will
form the basis for studies of replicase protein involvement in
host pathogenesis, virus-cell interactions, and virus comple-
mentation and new approaches to the development of stably
attenuated animal and human coronaviruses.
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